Katra Senica1, Ales Tomazic2, Ales Skvarca3, Petra Kolenc Peitl1, Renata Mikolajczak4, Alicja Hubalewska-Dydejczyk5, Luka Lezaic6. 1. Department of Nuclear Medicine, University Medical Centre Ljubljana, Zaloska 7, 1525, Ljubljana, Slovenia. 2. Department of Abdominal Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia. 3. Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia. 4. Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland. 5. Nuclear Medicine Unit, Department of Endocrinology, Jagiellonian University Medical School, Kraków, Poland. 6. Department of Nuclear Medicine, University Medical Centre Ljubljana, Zaloska 7, 1525, Ljubljana, Slovenia. luka.lezaic@kclj.si.
Abstract
PURPOSE: Insulinomas are the most common functioning neuroendocrine neoplasms of the pancreas, typically diagnosed due to characteristic symptoms. In the vast majority, the treatment is surgical and curative, requiring accurate localization of the tumour; conventional imaging, including somatostatin receptor molecular imaging, is negative in up to 10 % of cases. Recently, labelled glucagon-like peptide receptor (GLP-1R) analogues were introduced as a sensitive diagnostic method for localization of insulinomas. The aim of this study was to assess the diagnostic accuracy of a Tc-99m-labelled GLP-1R agonist [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4 for localization of occult insulinoma. PROCEDURES: Eight patients (all females; age range 35-75 years) with biochemically proven insulinoma and with negative or inconclusive conventional imaging (consisting of somatostatin receptor scintigraphy, computed tomography, endoscopic ultrasound and magnetic resonance imaging) were enrolled. Whole-body single-photon emission tomography/computed tomography (SPECT/CT) imaging was performed 4 h post-injection of 740 MBq of [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4. Surgical treatment was performed based on imaging findings. Histology of the removed lesions and biochemical and clinical symptom resolution was considered as the gold standard for analysis of the imaging results. RESULTS: Focal uptake of [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4 was found in all patients, leading to successful removal of the offending lesion and complete biochemical and symptomatic resolution. Histological analysis confirmed insulinoma in all included patients. CONCLUSIONS: [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4 SPECT/CT appears to be an excellent molecular imaging method for preoperative localization of an occult insulinoma, surpassing conventional imaging methods. If routinely available, it could be considered as a method of choice due to its favorable combination of imaging characteristics.
PURPOSE:Insulinomas are the most common functioning neuroendocrine neoplasms of the pancreas, typically diagnosed due to characteristic symptoms. In the vast majority, the treatment is surgical and curative, requiring accurate localization of the tumour; conventional imaging, including somatostatin receptor molecular imaging, is negative in up to 10 % of cases. Recently, labelled glucagon-like peptide receptor (GLP-1R) analogues were introduced as a sensitive diagnostic method for localization of insulinomas. The aim of this study was to assess the diagnostic accuracy of a Tc-99m-labelled GLP-1R agonist [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4 for localization of occult insulinoma. PROCEDURES: Eight patients (all females; age range 35-75 years) with biochemically proven insulinoma and with negative or inconclusive conventional imaging (consisting of somatostatin receptor scintigraphy, computed tomography, endoscopic ultrasound and magnetic resonance imaging) were enrolled. Whole-body single-photon emission tomography/computed tomography (SPECT/CT) imaging was performed 4 h post-injection of 740 MBq of [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4. Surgical treatment was performed based on imaging findings. Histology of the removed lesions and biochemical and clinical symptom resolution was considered as the gold standard for analysis of the imaging results. RESULTS: Focal uptake of [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4 was found in all patients, leading to successful removal of the offending lesion and complete biochemical and symptomatic resolution. Histological analysis confirmed insulinoma in all included patients. CONCLUSIONS: [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-exendin-4 SPECT/CT appears to be an excellent molecular imaging method for preoperative localization of an occult insulinoma, surpassing conventional imaging methods. If routinely available, it could be considered as a method of choice due to its favorable combination of imaging characteristics.
Authors: D L Morganstein; D H Lewis; J Jackson; A Isla; J Lynn; D Devendra; K Meeran; J F Todd Journal: Eur Radiol Date: 2009-07-14 Impact factor: 5.315
Authors: Michael Gabriel; Clemens Decristoforo; Eveline Donnemiller; Hanno Ulmer; Christine Watfah Rychlinski; Stephen J Mather; Roy Moncayo Journal: J Nucl Med Date: 2003-05 Impact factor: 10.057
Authors: Emanuel Christ; Damian Wild; Susanne Ederer; Martin Béhé; Guillaume Nicolas; Martyn E Caplin; Michael Brändle; Thomas Clerici; Stefan Fischli; Christoph Stettler; Peter J Ell; Jochen Seufert; Beat Gloor; Aurel Perren; Jean Claude Reubi; Flavio Forrer Journal: Lancet Diabetes Endocrinol Date: 2013-07-25 Impact factor: 32.069
Authors: Jean-Marc Guettier; Anthony Kam; Richard Chang; Monica C Skarulis; Craig Cochran; H Richard Alexander; Steven K Libutti; James F Pingpank; Phillip Gorden Journal: J Clin Endocrinol Metab Date: 2009-02-03 Impact factor: 5.958
Authors: Zhanhong Wu; Shuanglong Liu; Indu Nair; Keiko Omori; Stephen Scott; Ivan Todorov; John E Shively; Peter S Conti; Zibo Li; Fouad Kandeel Journal: Theranostics Date: 2014-05-24 Impact factor: 11.556
Authors: Thomas J Clough; Nicoleta Baxan; Emma J Coakley; Charlotte Rivas; Lan Zhao; Isabelle Leclerc; Aida Martinez-Sanchez; Guy A Rutter; Nicholas J Long Journal: Dalton Trans Date: 2020-04-15 Impact factor: 4.390